Shopping Cart 0
Cart Subtotal
USD 0

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Pipeline Review, H2 2017

Summary

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 8 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology and Respiratory which include indications Parkinson's Disease, Neurodegenerative Diseases, Glaucoma, Lung Disease and Pulmonary Hypertension.

The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2-Pipeline Review, H2 2017, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Overview

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Companies Involved in Therapeutics Development

Arrien Pharmaceuticals LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

H. Lundbeck AS

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

Oncodesign SA

Origenis GmbH

Pfizer Inc

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Drug Profiles

Antisense Oligonucleotides to Inhibit LRRK2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-1104-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-151-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-7915-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1337-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ODS-2005294-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06447475-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LRRK-2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK-2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases and Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-9444-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Dormant Products

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)-Product Development Milestones

Featured News & Press Releases

Dec 20, 2017: Denali Therapeutics Provides Update on DNL

Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease

May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases

May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors

Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago

Sep 09, 2014: Arrien Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B

Aug 16, 2012: Arrien Pharma'sORS-1104 Advances Into Investigational New Drug Enabling Stage

May 05, 2012: Arrien Pharma Provides Update On ORS-1104 For Treatment Of Parkinson'sDisease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Pipeline by D. Western Therapeutics Institute Inc, H2 2017

Pipeline by Denali Therapeutics Inc, H2 2017

Pipeline by H. Lundbeck AS, H2 2017

Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Pipeline by Lead Discovery Center GmbH, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Oncodesign SA, H2 2017

Pipeline by Origenis GmbH, H2 2017

Pipeline by Pfizer Inc, H2 2017

Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Arrien Pharmaceuticals LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

H. Lundbeck AS

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

Oncodesign SA

Origenis GmbH

Pfizer Inc